Abivax Showcases Obefazimod at the ECCO Congress
Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) has officially announced its participation at the upcoming European Crohn’s and Colitis Organization's 20th Annual Congress. This prestigious event, taking place from February 19-22, 2025, in Berlin, presents a significant opportunity for the company to showcase its lead drug candidate, obefazimod, which is being investigated for the treatment of moderately to severely active ulcerative colitis (UC).
Significant Research Findings
Abivax is set to present seven scientific abstracts focused on the clinical profile of obefazimod. During this congress, Abivax aims to engage with the inflammatory bowel disease community, sharing critical insights derived from its Phase 3 clinical trials.
Key Presentations on Obefazimod
Among the notable presentations at the congress is an oral presentation titled "Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QD." This study was led by Prof. Silvio Danese, a prominent figure in gastroenterology. He will present the findings during a digital oral presentation on February 21, 2025.
Moreover, several poster presentations will delve into various aspects of obefazimod treatment. These include its effectiveness on histological outcomes and health-related quality of life (HRQOL) among patients. Notably, renowned experts, including Dr. Fernando Magro and Dr. Séverine Vermeire, will present their insights at the event.
Abivax's Commitment to Research and Development
Abivax's dedication to advancing innovative therapies is at the forefront of its agenda. Obefazimod has shown promise in previous studies, showcasing its capability to manage UC effectively by stabilizing the immune response in patients. This aligns with Abivax's mission to develop products that harness the body's mechanisms to combat chronic inflammatory diseases.
Future Directions for Obefazimod
The findings presented at ECCO 2025 are anticipated to contribute significantly to the understanding and treatment of ulcerative colitis. With a focus on obefazimod's maintenance treatment, researchers are keen to explore long-term treatment patterns and patient outcomes in greater detail.
Abivax is breaking new ground, not only in treatment but also in the promotion of ongoing conversation within the medical community. This congress serves as a platform for exchanging ideas and fostering collaborations that could potentially change the treatment landscape for patients with UC.
Meet Abivax at ECCO
Conference attendees are encouraged to visit the Abivax booth (booth #30) for more insights on their ongoing research and the developments of obefazimod. This interaction fosters a rich dialogue between researchers, clinicians, and industry professionals, all aiming to improve patient outcomes.
About Abivax
Abivax stands as a beacon in the biotech sector, focused on creating therapies harnessing natural immune regulation. Based both in France and the United States, the company is leading the charge into innovative treatment protocols for chronic inflammatory diseases. Its commitment to research is evident with obefazimod (ABX464) currently in critical Phase 3 clinical trials.
Contact Information
If you would like more information, please reach out to:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878
Frequently Asked Questions
What is the main focus of the presentations by Abivax at ECCO 2025?
The presentations will primarily highlight the efficacy and safety of obefazimod in treating moderately to severely active ulcerative colitis.
Who are the key presenters representing Abivax?
Notable presenters include Prof. Silvio Danese and Dr. Séverine Vermeire, among others, who are recognized experts in gastroenterology.
What are the expected outcomes of the presented research?
The research is expected to enhance understanding of treatment outcomes and long-term patient management using obefazimod.
How can attendees engage with Abivax at the congress?
Attendees are invited to visit the Abivax booth (booth #30) for insights and discussions regarding their ongoing research.
What is the significance of obefazimod in UC treatment?
Obefazimod represents a novel approach to managing ulcerative colitis by stabilizing the immune response and improving patient outcomes.
